Eiry Roberts - 27 Apr 2026 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
27 Apr 2026
Net transactions value
$0
Form type
4
Filing time
27 Apr 2026, 16:41:52 UTC
Previous filing
06 Jun 2025
Next filing
20 May 2026
SEC
View on sec.gov

Key filing fact

Eiry Roberts filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 27 Apr 2026.

Key facts

  • This page summarizes Eiry Roberts's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
  • 6 reported transactions and 5 derivative rows are listed below.
  • Filing timestamp: 27 Apr 2026, 16:41.

Change

  • Previous filing in this sequence was filed on 06 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001727606 Primary reporting owner

ROBERTS EIRY

Relationship
Director
Address
47 HULFISH STREET, PRINCETON
Signature
/s/ Christian Formica, Attorney-in-Fact
Signature date
27 Apr 2026

Transactions Table

FOLD transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-76,275
Change %
-100%
Price
$14.50*
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Footnotes
F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares
-40,625
Change %
-100%
Price
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,625
Exercise price
$10.71
Footnotes
F2, F3
FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares
-45,423
Change %
-100%
Price
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
45,423
Exercise price
$8.55
Footnotes
F2, F3
FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares
-30,474
Change %
-100%
Price
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,474
Exercise price
$12.62
Footnotes
F2, F3
FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares
-42,467
Change %
-100%
Price
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,467
Exercise price
$10.27
Footnotes
F2, F3
FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares
-74,872
Change %
-100%
Price
Shares after
0
Date
27 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
74,872
Exercise price
$5.96
Footnotes
F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Eiry Roberts is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2 In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3 Each Option was fully vested.
F4 Each Option vested in full in connection with consummation of the Merger.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .